Evidence map›Paper›PMID 39530702›Full record

ArticleMicrobiology resource announcements2024

Genomic surveillance of SARS-CoV-2 in Nepal.

Binod Khadka, Rajindra Napit, Kathie A Mihindukulasuriya, Smita Shrestha, Ramanuj Rauniyar, Eans T Tuladhar, Lindsay Droit, Anne M Paredes, Runa Jha, Roji Raut and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology resource announcements, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Binod KhadkaCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Rajindra NapitCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Kathie A MihindukulasuriyaDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Smita ShresthaCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Ramanuj RauniyarCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Eans T TuladharCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Lindsay DroitDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Anne M ParedesDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Runa JhaNational Public Health Laboratory, Teku, Kathmandu, Nepal.
Roji RautCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Bimalesh K JhaNational Public Health Laboratory, Teku, Kathmandu, Nepal.
Scott A HandleyDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-2143-6570
Annie Elong-NgonoCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
Sujan ShrestaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.ORCID 0000-0003-2906-8474
David WangDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-0827-196X
Krishna D ManandharCentral Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.ORCID 0000-0002-6798-4935

Funding

Emerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0M
NIAID NIH HHS U01 AI151810NIH HHS U01AI151810
6 · The paper itself

Abstract

During the COVID-19 pandemic, Nepal, like other countries, faced emerging SARS-CoV-2 variants. To evaluate the circulating variants, 278 samples collected between September 2021 and March 2022 were sequenced in the country. From these, 229 high-quality genomes were obtained (82.97% Omicron and 17.03% Delta) highlighting the genomic diversity of SARS-CoV-2 in Nepal.

Indexed as

coronavirusCOVID-19Illuminawhole-genome sequencing

Identifiers

PMID39530702
PMCPMC11636318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.